$Recursion Pharmaceuticals (RXRX.US)$ Recursion Pharmaceutic...
$Recursion Pharmaceuticals (RXRX.US)$
Recursion Pharmaceuticals released an updated investor presentation on January 12, 2026, highlighting significant progress in its AI-native drug discovery platform. The company reported $755 million in year-end 2025 cash, providing expected runway through year-end 2027, with anticipated 2026 cash burn of less than $390 million.
Recursion Pharmaceuticals released an updated investor presentation on January 12, 2026, highlighting significant progress in its AI-native drug discovery platform. The company reported $755 million in year-end 2025 cash, providing expected runway through year-end 2027, with anticipated 2026 cash burn of less than $390 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
宇宙合一 : Recursion Pharmaceuticals released an updated investor presentation on January 12, 2026, highlighting significant progress in its AI-native drug discovery platform. The company reported having $755 million in cash as of the end of 2025, which is expected to support operations through the end of 2027, with a projected cash burn of less than $390 million for 2026.
The presentation showcased the company’s clinical achievements, including REC-4881, the first AI-supported clinical proof-of-concept drug that has the potential to become the first-in-class treatment for Familial Adenomatous Polyposis (FAP). Through successful partnerships with companies like Sanofi, Roche, and Genentech, Recursion has cumulatively achieved over $500 million in upfront and milestone payments.
The company maintains a focused clinical pipeline with approximately five projects in clinical development and 15 projects in the discovery stage. Key upcoming milestones include engaging with the FDA on REC-4881 in the first half of 2026, data releases from Phase 1/2 trials for multiple programs, and continued advancement of partnership programs. Recursion emphasizes its end-to-end AI-native platform capabilities from discovery to clinical development, supported by its proprietary supercomputer, BioHive-2.
宇宙合一 : Did you accidentally add an extra hundred million?
rocknrolln 宇宙合一 : That looks correct to me.. probably copy/paste from the article.. being lazy now but i think 2026 burn is estimated at high 300mm and runway is to eoy 2027